Bioject gets cash in undisclosed needle project:
This article was originally published in Clinica
Executive Summary
Bioject Medical Technologies is to receive $500,000, of which $150,000 is subject to milestones, from an unnamed "major biotechnology company" to cover the evaluation of the Portland, Oregon-based Bioject's compressed gas needlefree drug delivery system. Bioject hopes the deal will lead to a long-term licensing and supply agreement to use the device to deliver certain biopharmaceutical products.
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.